Analysis Orphazyme A/S (0CUM)
5/28/2024
Analysis of Orphazyme A/S (0CUM)
Orphazyme A/S is a biopharmaceutical company that focuses on developing treatments for neurodegenerative orphan diseases. The company has faced some challenges in recent times, including fluctuations in its stock price and regulatory hurdles for its lead drug candidate, arimoclomol.Looking at the provided data, we can see that the RSI indicator for Orphazyme A/S is not available for most of the historical data points. This may indicate a lack of consistent trend strength in the stock price movement.
The MACD indicator is also not available for the provided data points, which makes it difficult to assess the momentum of the stock price.
Overall, based on the limited data provided, it is important to conduct a more in-depth analysis of Orphazyme A/S, taking into consideration additional financial metrics, news, and developments related to the company. It is also crucial to monitor any regulatory updates regarding its drug candidates to better understand the potential future performance of the company.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at this time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company. Here is a summary of the key data points:Financials:
- Cash Flow: Operating cash flow TTM is $110,563,000,320 and levered free cash flow TTM is $84,726,874,112.
- Balance Sheet: Total cash MRQ is $67,150,000,128, total debt MRQ is $104,590,000,128, current ratio MRQ is 1.037, book value per share MRQ is $4.837, total cash per share MRQ is $4.379, and total debt to equity MRQ is 140.968.
- Profit Margin: 26.306%
- Fiscal Year Ends: September 30, 2023
- Income Statement: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.44, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth YoY is -2.2%.
- Operating Margin: 30.743%
- Return on Assets TTM: 22.073999%
- Return on Equity TTM: 147.25%
- Most Recent Quarter: March 31, 2024
Stock Statistics:
- Short Ratio: 1.66
- Float Shares: 15,308,320,742
- Shares Short: 94,308,265
- Average 10-Day Volume: 52,903,608
- Average 90-Day Volume: 62,823,269
- Shares Outstanding: 15,334,099,968
- Percent Held by Insiders: 5.22%
- Percent Held by Institutions: 57.555%
- Short Percent of Shares Outstanding: 0.62%
Valuation Metrics:
- PEG Ratio: 26.213001
- Forward PE: 26.213001
- Trailing PE: 29.428572
- Enterprise Value: $2,948,462,018,560
- Price to Book MRQ: 39.181313
- Price to Sales TTM: 7.6151557
- Enterprise to EBITDA: 22.745
- Enterprise to Revenue: 7.726
- Market Capitalization: $2,906,118,684,672
Stock Price Summary:
- Beta: 1.264
- 50-Day Moving Average: $173.6936
- 200-Day Moving Average: $180.7906
- 52-Week Low: $164.08
- 52-Week High: $199.62
- 52-Week Change: 8.253%
Dividends and Splits:
- Payout Ratio: 14.93%
- Dividend Date: May 16, 2024
- Last Split Date: August 31, 2020
- Ex-Dividend Date: May 10, 2024
- Last Split Factor: 4-for-1 split
- Forward Annual Dividend Rate: $1
- 5-Year Average Dividend Yield: 0.73%
- Forward Annual Dividend Yield: 0.5266761603816345%
- Trailing Annual Dividend Rate: $0.97
- Trailing Annual Dividend Yield: 0.5108758755701854%
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. It is important to note that these are analyst estimates and actual performance may vary.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions regarding the future price of the security, with the average and median both indicating a price higher than the current price. It is important to consider these forecasts along with other factors when making investment decisions.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite fluctuations in other financial metrics, the gross profit has generally followed the trend of increasing sales revenue, indicating healthy margins.
3. The company has been able to maintain a stable EBITDA margin, with EBITDA increasing along with sales revenue.
4. Net income has also shown a positive trend, increasing from $57.4 billion in 2020 to $97 billion in 2023.
5. The company has effectively managed its operating expenses, as seen in the consistent growth of operating income over the years.
6. Despite variations in other income and expenses, the company has been able to generate consistent net income from continuous operations.
7. The basic and diluted earnings per share (EPS) have shown an increasing trend, reflecting the growth in net income and the company's share buyback activities.
8. The company's effective tax management is evident from the stable income tax expenses relative to the increasing revenues.
9. Overall, the financial performance of the company, as indicated by the revenue figures, shows a positive growth trajectory over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with cash and cash equivalents showing fluctuations.
3. Non-current assets consist of leases, land, investments, and machinery, with investments and advances showing an increasing trend.
4. Total liabilities have also been increasing, with the highest value of $302,083,000,000 in 2022.
5. Current liabilities include short-term debt, accounts payable, and deferred revenue.
6. Non-current liabilities consist of long-term debt and other non-current liabilities.
7. Shareholders' equity has shown variations, with the highest value of $90,488,000,000 in 2019.
8. Common stock and retained earnings are part of shareholders' equity.
9. The company has been investing in machinery, equipment, and advances over the years.
10. The company has been managing its short-term and long-term debts along with other liabilities.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Number of Analysts: 26
- Year Ago EPS: $1.26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Number of Analysts: 25
- Year Ago EPS: $1.46
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Number of Analysts: 39
- Year Ago EPS: $6.13
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Number of Analysts: 39
- Year Ago EPS: $6.59
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two fiscal years. It indicates growth in earnings compared to the previous year, with the highest growth expected in the next year (2025).
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
